TD Cowen Reiterates Buy Rating on Exact Sciences (EXAS)

TD Cowen analyst Dan Brennan reiterated a Buy rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS).

The analyst commented, "EXAS has underperformed owing to a # of concerns: 2H-weighted guide, S&M investment clouds margin story & increased competition, notably blood. The first 2 are more straight forward to address, while assessing blood's impact will take time. Our take: over the next 12+ months investors should be rewarded (78% upside to our PT) owning EXAS at current levels as visibility improves on these factors."

For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.

Shares of Exact Sciences closed at $44.85 yesterday.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Magellan Aerospace (MAL) Declares $0.05 Quarterly Dividend; 2.2% Yield
• Rio Grande Resources plans $2.5M private placement financing